We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
MRI features predict tumor grade in isocitrate dehydrogenase (IDH)–mutant astrocytoma and oligodendroglioma.
- Authors
Joyner, David A.; Garrett, John; Batchala, Prem P.; Rama, Bharath; Ravicz, Joshua R.; Patrie, James T.; Lopes, Maria-B.; Fadul, Camilo E.; Schiff, David; Jain, Rajan; Patel, Sohil H.
- Abstract
Purpose : Nearly all literature for predicting tumor grade in astrocytoma and oligodendroglioma pre-dates the molecular classification system. We investigated the association between contrast enhancement, ADC, and rCBV with tumor grade separately for IDH-mutant astrocytomas and molecularly-defined oligodendrogliomas. Methods: For this retrospective study, 44 patients with IDH-mutant astrocytomas (WHO grades II, III, or IV) and 39 patients with oligodendrogliomas (IDH-mutant and 1p/19q codeleted) (WHO grade II or III) were enrolled. Two readers independently assessed preoperative MRI for contrast enhancement, ADC, and rCBV. Inter-reader agreement was calculated, and statistical associations between MRI metrics and WHO grade were determined per reader. Results: For IDH-mutant astrocytomas, both readers found a stepwise positive association between contrast enhancement and WHO grade (Reader A: OR 7.79 [1.97, 30.80], p = 0.003; Reader B: OR 6.62 [1.70, 25.82], p = 0.006); both readers found that ADC was negatively associated with WHO grade (Reader A: OR 0.74 [0.61, 0.90], p = 0.002); Reader B: OR 0.80 [0.66, 0.96], p = 0.017), and both readers found that rCBV was positively associated with WHO grade (Reader A: OR 2.33 [1.35, 4.00], p = 0.002; Reader B: OR 2.13 [1.30, 3.57], p = 0.003). For oligodendrogliomas, both readers found a positive association between contrast enhancement and WHO grade (Reader A: OR 15.33 [2.56, 91.95], p = 0.003; Reader B: OR 20.00 [2.19, 182.45], p = 0.008), but neither reader found an association between ADC or rCBV and WHO grade. Conclusions: Contrast enhancement predicts WHO grade for IDH-mutant astrocytomas and oligodendrogliomas. ADC and rCBV predict WHO grade for IDH-mutant astrocytomas, but not for oligodendrogliomas.
- Subjects
GENETIC mutation; PREDICTIVE tests; CONFIDENCE intervals; GLIOMAS; MAGNETIC resonance imaging; RETROSPECTIVE studies; ACQUISITION of data; CONTRAST media; TUMOR classification; INTER-observer reliability; MEDICAL records; DESCRIPTIVE statistics; METHICILLIN resistance; OXIDOREDUCTASES; ODDS ratio
- Publication
Neuroradiology, 2023, Vol 65, Issue 1, p121
- ISSN
0028-3940
- Publication type
Article
- DOI
10.1007/s00234-022-03038-0